Found: 18
Select item for more details and to access through your institution.
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1633, doi. 10.1007/s10637-021-01149-8
- By:
- Publication type:
- Article
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e249, doi. 10.1016/j.clml.2019.09.412
- By:
- Publication type:
- Article
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e14, doi. 10.1016/j.clml.2017.03.024
- By:
- Publication type:
- Article
Phase I/ II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 3, p. 321, doi. 10.1111/bjh.12129
- By:
- Publication type:
- Article
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 5, p. 580, doi. 10.1111/j.1365-2141.2011.08884.x
- By:
- Publication type:
- Article
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
- Published in:
- British Journal of Haematology, 2006, v. 135, n. 2, p. 174, doi. 10.1111/j.1365-2141.2006.06280.x
- By:
- Publication type:
- Article
The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
- Published in:
- Oncologist, 2020, v. 25, n. 3, p. e451, doi. 10.1634/theoncologist.2019-0291
- By:
- Publication type:
- Article
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 60, doi. 10.1111/bjh.14992
- By:
- Publication type:
- Article
Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.
- Published in:
- Magnetic Resonance in Medicine, 2017, v. 77, n. 2, p. 814, doi. 10.1002/mrm.26167
- By:
- Publication type:
- Article
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 2, p. 180, doi. 10.1002/jcph.988
- By:
- Publication type:
- Article
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 1, p. 114, doi. 10.1002/jcph.987
- By:
- Publication type:
- Article
Denosumab for treatment of hypercalcemia of malignancy.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 3, p. 583, doi. 10.1007/s00280-014-2529-2
- By:
- Publication type:
- Article
Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.
- Published in:
- Journal of Hematology & Oncology, 2018, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13045-018-0612-6
- By:
- Publication type:
- Article
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 10, p. 1288, doi. 10.1002/jcph.719
- By:
- Publication type:
- Article
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
- Published in:
- International Journal of Cancer, 2016, v. 139, n. 1, p. 177, doi. 10.1002/ijc.30049
- By:
- Publication type:
- Article